Pliant Therapeutics Announces Positive Data from the

Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No...

Related Keywords

,Group Demonstrated Strong Treatment ,Pliant Therapeutics Inc ,Bexotegrast Clinical Development Next ,Nasdaq ,Quantitative Lung Fibrosis ,Well Tolerated ,Serious Adverse ,Group Demonstrated Strong Treatment Effects ,Profibrotic Biomarkers Versus Placebo ,Mixed Model Repeat Measures Analysis ,Modified Intent ,Forced Vital Capacity ,Nasdaq Plrx ,Pliant Therapeutics ,Nc ,